DexCom vs Ypsomed vs Insulet and 1 More Revenue Comparison
Compare financial metrics side-by-side using real SEC EDGAR data
Revenue Comparison
Chart: Revenue Comparison. Values in USD billions. In Q3 2026: DexCom 1.345, Ypsomed 0.12, Insulet 0.842, West Pharmaceutical Services 0.875.
* Ypsomed reports semi-annually. Values are evenly split across both quarters within each half.
Latest Quarter Comparison
Table: Latest Quarter Comparison. 15 rows across Metric, DexCom, Ypsomed, Insulet, West Pharmaceutical Services.| Metric | DexCom | Ypsomed | Insulet | West Pharmaceutical Services |
|---|---|---|---|---|
| Market Cap | $30.24B | $6.36B | $10.39B | $28.78B |
| Revenue | $1.34B | $416.00M | $842.00M | $875.00M |
| Cost of Revenue | $480.00M | $230.00M | $210.00M | $527.00M |
| Gross Profit | $864.00M | $186.00M | $632.00M | $347.00M |
| Operating Income | $327.00M | $124.00M | $190.00M | $267.00M |
| Net Income | $275.00M | $94.00M | $141.00M | $214.00M |
| R&D Expense | $162.00M | $24.00M | $92.00M | $18.00M |
| Earnings Per Share | $0.72 | $6.9 | $2.03 | $3.02 |
| Gross Margin | 64.3% | 44.6% | 75.1% | 39.7% |
| Operating Margin | 24.3% | 29.8% | 22.5% | 30.6% |
| Net Profit Margin | 20.5% | 22.5% | 16.8% | 24.5% |
| Free Cash Flow | $273.00M | $8.00M | $66.00M | $150.00M |
| Cumulative Free Cash Flow | $3.67B | $-64.00M | $28.00M | $3.75B |
| Operating Cash Flow | $326.00M | $199.00M | $123.00M | $190.00M |
| Cash & Equivalents | $961.00M | $32.00M | $584.00M | $464.00M |